Fusion protein containing TGF-β receptor and medicinal uses thereof
US11274142B2 · kind B2 · utility
1Cited by
0References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 11, 2018 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | Jul 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a fusion protein containing TGF-β receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-βRII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-β receptor, and the use thereof in the preparation of anti-cancer drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.